Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells (Q79188374)
Jump to navigation
Jump to search
scientific article published on 01 October 2006
Language | Label | Description | Also known as |
---|---|---|---|
English | Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells |
scientific article published on 01 October 2006 |
Statements
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells (English)
Warren Fiskus
Michael Pranpat
Maria Balasis
Purva Bali
Veronica Estrella
Sandhya Kumaraswamy
Rekha Rao
Kathy Rocha
Bryan Herger
Francis Lee
Victoria Richon